CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 45 enrolled
Drug / intervention
NS2 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02406209
NCT02406209Phase 2Completed
CompareCT.gov

A Phase 2 Randomized, Investigator-Masked, Comparator-controlled Trial to Evaluate the Safety and Efficacy of NS2 Eye Drops in Patients With Anterior Uveitis

Aldeyra Therapeutics, Inc.·interventional·Posted Apr 2, 2015·Updated Mar 27, 2023

In Brief

A Phase 2 clinical trial evaluating NS2 and Prednisolone acetate ophthalmic suspension (1%) for Non-infectious Anterior Uveitis. Completed, enrolled 45 participants across 15 sites.

Detailed Summary

This is a randomized, multi-center, investigator masked, comparator controlled study. The purpose of this study is to determine the efficacy and safety of NS2 in patients with non-infectious acute anterior uveitis. Subjects will be randomized 1:1:1 to receive multiple doses of NS2 0.5%, NS2 0.5% and Pred Forte® 1%, or Pred Forte® 1%. Free aldehydes are thought to be related to inflammatory diseases such as uveitis. NS2, a small molecule aldehyde trap, may decrease inflammation by lowering aldehyde levels.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-infectious Anterior Uveitis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedApr 2, 2015
Enrollment StartMar 1, 2015
Primary CompletionApr 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 11.3 years ago

Interventions

NS2drug

NS2 ophthalmic drops (0.5%)

Prednisolone acetate ophthalmic suspension (1%)drug